Eli Lilly and Company
- Business Wire
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
– Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause…
Read More » - United States
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Ingelheim, Germany & Indianapolis, United States: – In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total…
Read More »